Please login to the form below

Not currently logged in
Email:
Password:

AZ

This page shows the latest AZ news and features for those working in and with pharma, biotech and healthcare.

AZ says dropping MedImmune will help ‘streamline’ its R&D

AZ says dropping MedImmune will help ‘streamline’ its R&D

The Gaithersburg, Maryland-headquartered company is the source of a chunk of AZ’s biologics pipeline, including cancer immunotherapy Imfinzi (durvalumab) and severe asthma drug Fasenra (benralizumab) that were both highlighted ... in the group’s

Latest news

More from news
Approximately 69 fully matching, plus 772 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Galbraith’s unit has not only demonstrated good judgement about picking winning molecules, but has also shown speed: Tagrisso is one of the fastest-ever developed drugs, with AZ taking it

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    Lastly, AZ has also gained three Breakthrough Therapy Designations (including two Orphan Drug Designations) and six additional Priority Review Designations. ... Jane Osbourn, AZ's site lead. The new HQ is specifically designed to foster an open,

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    years for AZ to return to top-line growth after the patent loss of blockbuster brands such as Nexium and Crestor. ... One such project was set up with the Wuxi regional government in 2017, where AZ established a joint venture.

  • Biopharma's Future: Made in China Biopharma's Future: Made in China

    So how does AZ ensure it doesn’t get entangled in bribery or corruption in China? ... AZ's Mark Mallon. “We have built the right culture there,” says Mallon.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    And AZ’s Imfinzi (durvalumab) meanwhile has shown its worth as a maintenance therapy to stop recurrence of earlier-stage, locally-advanced NSCLC. ... up innate immune responses, and Cancer Research UK is repurposing an AZ chemokine CCR4 receptor drug

More from intelligence
Approximately 3 fully matching, plus 47 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 35 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics